We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Morphosys (MOR) NPV

Sell:€33.20 Buy:€33.34 Change: €1.64 (4.69%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
Sell:€33.20
Buy:€33.34
Change: €1.64 (4.69%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
Sell:€33.20
Buy:€33.34
Change: €1.64 (4.69%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

MorphoSys AG develops and commercializes antibodies for therapeutic applications. The Company develops drugs using its own research and development, as well as in cooperation with pharmaceutical and biotechnology partners. The Company's operating segments include Proprietary Development and Partnered Discovery. In the Proprietary Development segment, it develops therapeutic antibodies and peptides in the area of inflammatory disease and oncology. In the Partnered Discovery segment, the Company applies technologies for the research, development and optimization of therapeutic antibodies as drug candidates. The Company develops new treatments for patients suffering from serious diseases. Its technologies include HuCAL, which is a collection fully human antibodies and a system for their optimization; Ylanthia, which is an antibody library in Fab format, and Slonomics, an automated technology for gene synthesis and modification for the generation of gene libraries in a controlled process.

Contact details

Address:
Semmelweisstr. 7
PLANEGG
82152
Germany
Telephone:
+49 (89) 899270
Website:
https://www.morphosys.de/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
MOR
ISIN:
DE0006632003
Market cap:
€1.19 billion
Shares in issue:
34.14 million
Sector:
Biotechnology
Exchange:
Frankfurt Stock Exchange
Country:
Germany
Currency:
Euro
Indices:
n/a

Key personnel

  • Marc Cluzel
    Independent Chairman of the Supervisory Board
  • Jean-Paul Kress
    Chief Executive Officer
  • George Golumbeski
    Independent Deputy Chairman Member of the Supervisory Board
  • Sung Lee
    Chief Financial Officer
  • David Trexler
    President - MorphoSys US Inc
  • Malte Peters
    Chief Development Officer , Member of the Management Board
  • Roland Wandeler
    Chief Commercial Officer, Member of the Management Board

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.